Skip to main content
Publications
de Vogel S, Seeger JD, Arana A , Margulis AV , McQuay LJ, Perez-Gutthann S , Hallas J, Kristiansen NS, Linder M, Odsbu I, Suehs B, Xu Y, Uribe C, Appenteng K, Robinson NJ. Lessons learned from a multi-data source research collaboration: the mirabegron post-authorization safety study program . Pharmacoepidemiol Drug Saf. 2024 May;33(5):e5799. doi: 10.1002/pds.5799
Saltus C , Djibo DA, Peetluk L, Kaye J, McMahill-Walraven C, Johannes C , Bernick B, Calingaert B , Franklin J, Graham S, Pigoga J, Shuminski P, Margulis AV . Use of very low-dose vaginal estrogens among postmenopausal women in the US . Poster presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):352-3. doi: 10.1002/pds.5687
Pajouheshnia R , Gini R, Hyde E, Swertz MA, Sturkenboom M, Margulis AV , Franzoni C , Arana A , Ehrenstein V, Gembert K, Jansen E, Herings RMC, Thurin NH, Locatelli I, Jazbar J, Zerovnik S, Kos M, Smit S, Lind S, Metspalu A, Zaccagnino S, Busto MP, Middelkoop B, Barreiro-de Acosta M, Saez FS, Rodriguez-Bernal C, Sanfelix-Gimeno G, Poblador-Plou B, Carmona-Pirez J, Gimeno-Miguel A, Gil M, Schafer W, Haug U, Simou S, Hedenmalm K, Cochino A, Alcini P, Kurz X, Gutierrez L , Perez-Gutthann S . MINERVA: Metadata for data dIscoverability aNd study rEplicability in obseRVAtional studies . Poster presented at the 2022 ICPE Conference; August 28, 2022. Copenhagen, Denmark. [abstract] Pharmacoepidemiol Drug Saf. 2022 Sep 23; 31(S2):564. doi: 10:1002/pds.5518
Arana A , Margulis AV , Varas-Lorenzo C, Bui CL , Gilsenan A , McQuay LJ, Reynolds M , Rebordosa C , Franks B, de Vogel S, Appenteng K, Perez-Gutthann S . Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom . Pharmacoepidemiol Drug Saf. 2021 Feb;30(2):237-47. doi: 10.1002/pds.5150
Margulis AV , D'Onofrio B, Almqvist C, McElrath T, Oberg AS, Plana E , Rothman KJ , Hernandez-Diaz S. Antiepileptic drugs in pregnancy and duration of pregnancy, birth weight, length, and head circumference . Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):234. doi: 10.1002/pds.4629
Didden E-M, Andrews EB, Hellwig K, Hernandez-Diaz S, Magyari M, Margulis AV , Rivero-Ferrer E , Bader-Weder S, Wormser D. A novel approach for active surveillance of pregnancy safety in multiple sclerosis . Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):268. doi: 10.1002/pds.4629
Krueger WS, Anthony MS , Saltus CW , Margulis AV , Rivero-Ferrer E , Monz B, Wormser D, Andrews E. Existing databases useful for pregnancy exposure and fetal outcomes research, case study in multiple sclerosis (MS) . Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 29, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):403. doi: 10.1002/pds
Arana A , Varas-Lorenzo C, McQuay LJ, Ziemiecki R , Bui CL , Gilsenan AW , Rothman KJ , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Margulis AV , Perez Gutthann S . Do individual antimuscarinic drugs to treat overactive bladder have different cardiovascular risks? A UK CPRD cohort study . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):534-5.
Margulis A , Houben E, Olesen M, Hallas J, Overbeek J, Pottegard A, Ye W, Villegas D, Perez-Gutthann S , Arana A . Drug utilization study: evaluation of the use of nepafenac in the Netherlands and Denmark . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):225.
Margulis AV , Varas-Lorenzo C, Bui CL , McQuay LJ, Ziemiecki R , Reynolds M , Rebordosa C , Pladevall-Vila M , Fortuny J , Rivero-Ferrer E , Plana E , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Arana A . Validation of cardiovascular events and covariates in CPRD GOLD using questionnaires to general practitioners (GPS) . Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):255-6.
Margulis AV , Linder M, Arana A , Pottegard A, Anveden-Berglind I, Bui CL , Kristiansen NS, Bahmanya S, McQuay LJ, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Hallas J. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):653.
Hallas J, Margulis AV , Pottegard A, Kristiansen N, Bui CL , Krueger W, Atsma WJ, Appenteng K, Franks B, de Vogel S, D 'Silva M, Perez-Gutthann S , Arana A . Incidence of cardiovascular events in new users of overactive bladder medications in Denmark . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):491.
Hallas J, Margulis AV , Pottegard A, Kaye JA, Kristiansen N, Bui CL , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Arana A . Elevated bladder and prostate cancer rates following initiation of OAB medication: findings from the Danish Registries . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):533.
Fortuny J , Kaye JA, Bui CL , Gilsenan AW , Bartsch J , Plana E , McQuay LJ, Calingaert B , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez Gutthan S , Arana A , Margulis AV . Evaluation of free-text comments to validate common cancer diagnoses in the UK CPRD . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58.
Linder M, Margulis AV , Anveden-Berglind I, Bahmanyar S, Bui CL , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Arana A . Cardiovascular risk in users of antimuscarinic drugs for overactive bladder: a cohort study in the Swedish National Registers . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):491-2.
Linder M, Margulis AV , Anveden-Berglind I, Bahmanyar S, Bui CL , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Arana A . Cancer risk in users of antimuscarinic drugs for overactive bladder: a cohort study in the Swedish National Registers . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):533-4.